Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?

Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism... Objective  Rearranged during transfection (RET) gene analysis, widely used to identify carriers at risk of medullary thyroid cancer (MTC), occasionally uncovers novel sequence ‘variants of unknown clinical significance’ including RET I852M. This study aimed to clarify whether RET I852M represents a harmless polymorphism or a pathogenic mutation. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Endocrinology Wiley

Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?

Loading next page...
 
/lp/wiley/germline-ret-sequence-variation-i852m-and-occult-medullary-thyroid-0oaZij1ZgY

References (17)

Publisher
Wiley
Copyright
Copyright © 2011 Wiley Subscription Services
ISSN
0300-0664
eISSN
1365-2265
DOI
10.1111/j.1365-2265.2011.04158.x
pmid
21711375
Publisher site
See Article on Publisher Site

Abstract

Objective  Rearranged during transfection (RET) gene analysis, widely used to identify carriers at risk of medullary thyroid cancer (MTC), occasionally uncovers novel sequence ‘variants of unknown clinical significance’ including RET I852M. This study aimed to clarify whether RET I852M represents a harmless polymorphism or a pathogenic mutation.

Journal

Clinical EndocrinologyWiley

Published: Jan 1, 2011

There are no references for this article.